A clinical-stage biotech developing experimental drugs for COVID-19 respiratory failure and bipolar depression with suicidal thoughts, none yet approved or generating revenue.
No revenue from any product; the company burns cash, with net losses of USD 0.03B in 2025 and operating losses each quarter. Money comes only from investor funding, not sales.
No approved products or proprietary platform competitors like Pfizer or Johnson & Johnson can't replicate; any moat would depend on clinical trial results that haven't materialized.
None yet
None yet
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
